Mariposa Therapeutics
Develops topical therapies for people with Epidermolysis Bullosa Simplex and other keratin-related conditions
Highlights
- New on EvolcAdded 2026-11-14
About Mariposa Therapeutics
Mariposa Therapeutics is developing MP5219, a topical treatment intended to activate compensatory keratins and address the skin-cell structural failure associated with Epidermolysis Bullosa Simplex. Its lead programme, MP5219-1, is being developed as a cream.
The company focuses on people with Epidermolysis Bullosa Simplex. The page describes completed drug discovery, lead optimisation, safety and efficacy studies, with formulation development, manufacturing scale-up and regulatory preparation underway; a first-in-human study is a planned next step.
Mariposa Therapeutics Limited was founded in 2019 and is headquartered in Cardiff, United Kingdom.
Product: MP5219-1, a topical cream in development for Epidermolysis Bullosa Simplex.
Jobs at Mariposa Therapeutics
More biotech & pharma companies
Matheus Engineering
Contract process engineering research and scale-up services for pharmaceutical and chemical manufacturersYoung companyNew on EvolcMatrix Science
Proteomics software for researchers and scientists identifying and quantifying proteins from mass spectrometry dataMaxion Therapeutics
Engineered protein therapeutics for ion channel- and GPCR-driven diseasesMC Diagnostics
Automated molecular diagnostics products and services for clinical laboratories and transplant and transfusion testingMC2 Therapeutics
Topical dermatology products, prescription and DermoCosmetic, for psoriasis and itchy, dry or sensitive skinMdbiologics
UK healthcare company with separate websites for healthcare professionals and members of the publicYoung company
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Hosting
- ApacheHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.